Advanced Medical Isotope Corporation Announces Participation in Upcoming Investment Conferences

KENNEWICK, WA/ ACCESSWIRE / May 27, 2016 / Advanced Medical Isotope Corporation (or “AMI”) (OTC: ADMD), a late stage development company engaged in the development of brachytherapy devices for therapeutic applications today announced that it will be presenting at two upcoming investor conferences. The first is the 5th Annual SeeThruEquity Microcap Investor Conference at Convene on 730 Third Avenue in New York City on May 31, 2016. The second is the 6th annual LD Micro Invitational on June 7th in Los Angeles.

AMI Founder, CEO and Chairman James C. Katzaroff stated, “With the recent filing of our 10K annual report, we now look forward to presenting to existing shareholders and new investors the significant progress in our capital restructuring plan as well as our regulatory and commercialization roadmap for 2016. We are very pleased with the results of our efforts to improve our balance sheet during 2015. We continue with our unshakable commitment to normalize our capital structure, having reduced our liabilities by over $11 million in 2015 and to continue our efforts commercialize our Y-90 RadioGel(TM) device and IsoPet Solutions.”

About Advanced Medical Isotope Corporation

Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non resectable tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our website, www.isotopeworld.com.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words “may,” “will,” “should,” “plans,” “expects,” “anticipates,” “continue,” “estimates,” “projects,” “intends,” and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company’s ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company’s control.

CONTACTS:

Advanced Medical Isotope
Corporation

James C. Katzaroff, CEO
1021 N Kellogg
Kennewick WA 99336
509-736-4000

Investors:

Circadian Group, IR
Tyler Troup, B. Comm
1-(866)-950-8300
info@circadian-group.com

SOURCE: Advanced Medical Isotope Corporation

ReleaseID: 440470